"Assuming the revenue is not shared 50:50 with an industry partner increases the estimated range to more than $64.74 to $116.40 per share"
There it is: the gap between $2 and $64-116 is the hurdle the market needs to jump - and they need to know that it IS possible to get there very quickly.
The roadmap to get there is slowly being played out. Our breakout moments will be tied to low availability of SOI, dramatic increase in FTO and $RAC awareness, and this comes from clinical results and BP dealmaking. All of this is happening now in 2023, to be played out over the next 24 months (based on RAC's own timeline of 24-36 months from March 2022).
This year is going to be pivotal.
- Forums
- ASX - By Stock
- RAC
- Why Analysts Believe RAC is “Highly Undervalued”
Why Analysts Believe RAC is “Highly Undervalued”, page-3
-
- There are more pages in this discussion • 132 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.19 |
Change
-0.030(2.46%) |
Mkt cap ! $197.8M |
Open | High | Low | Value | Volume |
$1.20 | $1.24 | $1.17 | $25.43K | 21.19K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 700 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.19 | 2856 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 700 | 1.160 |
1 | 6000 | 1.155 |
1 | 200 | 1.150 |
2 | 5887 | 1.140 |
2 | 18000 | 1.130 |
Price($) | Vol. | No. |
---|---|---|
1.190 | 2856 | 1 |
1.220 | 4562 | 1 |
1.235 | 5000 | 1 |
1.250 | 8894 | 2 |
1.295 | 5256 | 1 |
Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.19 |
  |
Change
-0.030 ( 1.25 %) |
|||
Open | High | Low | Volume | ||
$1.18 | $1.24 | $1.18 | 8334 | ||
Last updated 15.37pm 06/05/2024 ? |
Featured News
RAC (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online